Gepirone

Gepirone

150px
Systematic (IUPAC) name
4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
Clinical data
Routes of administration	Oral
Legal status
Legal status	Uncontrolled
Pharmacokinetic data
Biological half-life	2-3 hours
Identifiers
CAS Number	83928-76-1
ATC code	N06AX19 (WHO)
PubChem	CID 55191
Chemical data
Formula	C19H29N5O2
Molar mass	359.46586 g/mol[[]]

Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is a psychoactive drug and research chemical of the piperazine and azapirone chemical classes. It is currently under clinical development in an extended release form as an anxiolytic and antidepressant agent. Pharmacologically, gepirone acts as a selective 5-HT_1A receptor partial agonist.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. Fabre-Kramer and GlaxoSmithKline are evaluating the response from the FDA to determine appropriate next steps.

500px

Ormaza, V. A.; 1986, ES 8606333 .

See also

• Azapirone